Choose Your News
MorphoSys and Galapagos land upfront money from Novartis. Novartis sticks its own breakthrough in acute radiation syndrome. Mersana has a deadly setback in an e... [Read More]
Karyopharm makes its first big move in myeloma. Asterias inches forward in its spinal cord injury trial. Cellectar goes for a one-two punch in lymphoma. [Read More]
Eisai posts favorable top-line data in obesity. Omeros gets started on a trial to attack addiction and compulsive disorders. Cellectar times a reverse split wit... [Read More]
Array's melanoma combo gets a guideline nod. Atossa looks for a window of opportunity in breast cancer. Astellas and Pfizer score widened approval for Xtandi. [Read More]